Roche delays European giredestrant filing as US pricing policy reshapes global oncology

Summary

Pharmaceutical giant Roche is postponing the European regulatory submission for its oral SERD breast cancer treatment, giredestrant. This strategic pivot illustrates how US Medicare drug price negotiations are incentivizing manufacturers to delay international launches to protect global price floors.

This sits in Oncology and Therapeutics and changes the rules companies, insurers, and clinicians have to work within. Expect knock-on effects on what gets covered, how it gets paid for, and how quickly products can reach patients.

Sources

• OVUM Primary source